Adebrelimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | PD-L1 |
| Clinical data | |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| UNII | |
Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1.[1][2]
In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer.[3]
References
[edit]- ^ Gan Y, Shi F, Zhu H, Han S, Li D (2023). "Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing". Frontiers in Pharmacology. 14: 1241130. doi:10.3389/fphar.2023.1241130. PMC 10398383. PMID 37547339.
- ^ "Adebrelimab - Atridia". AdisInsight. Springer Nature Switzerland AG.
- ^ "New drugs approved by NMPA in 2023".
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |